Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy

This study tests whether adding sodium glycididazole — a drug that may help protect normal tissues from radiation damage — reduces side effects in people with unresectable (inoperable) non-small cell lung cancer who are receiving combined chemotherapy and radiation after initial treatment. **You may be eligible if...** - You have confirmed non-small cell lung cancer (NSCLC) - Your cancer is at an unresectable stage II or III after prior neoadjuvant (pre-treatment) therapy - You are in acceptable health (ECOG 0–2) with adequate organ function **You may NOT be eligible if...** - You have previously received radiation therapy - You have had prior immune-related lung inflammation (pneumonitis) of grade 2 or higher - Your cancer requires surgery - You have another primary cancer - You have a primary immune deficiency - Your cancer has mixed small cell and non-small cell features Talk to your doctor to see if this trial is right for you.